Johnson & Johnson (NYSE:JNJ) issued an update on its FY17 earnings guidance on Tuesday morning. The company provided EPS guidance of $7.25-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.18. The company issued revenue guidance of $76.1-76.5 billion, compared to the consensus revenue estimate of $75.84 billion.
Shares of Johnson & Johnson (NYSE JNJ) traded down 0.02% on Friday, reaching $141.78. The company’s stock had a trading volume of 5,140,654 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The stock has a 50-day moving average of $134.68 and a 200 day moving average of $131.18. The stock has a market capitalization of $380.54 billion, a PE ratio of 24.66 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.68%. The firm had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the company posted $1.68 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post $7.28 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.37%. Johnson & Johnson’s payout ratio is currently 58.33%.
Several equities research analysts recently commented on the stock. Vetr upgraded shares of Johnson & Johnson from a sell rating to a hold rating and set a $137.71 target price on the stock in a research report on Monday. Barclays PLC raised their price target on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an equal weight rating in a report on Wednesday, October 18th. BMO Capital Markets restated a positive rating and set a $152.00 price target (up previously from $145.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock an outperform rating in a report on Thursday, October 19th. Finally, Citigroup Inc. raised their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a buy rating in a report on Monday, October 23rd. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have issued a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus price target of $143.70.
ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/10/28/johnson-johnson-jnj-issues-fy17-earnings-guidance.html.
A number of institutional investors and hedge funds have recently modified their holdings of JNJ. Harding Loevner LP purchased a new stake in Johnson & Johnson in the second quarter worth approximately $106,000. IHT Wealth Management LLC boosted its stake in Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after buying an additional 3,467 shares in the last quarter. Mountain Capital Investment Advisors Inc purchased a new stake in Johnson & Johnson in the second quarter worth approximately $124,000. Lenox Wealth Management Inc. boosted its stake in Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after buying an additional 24 shares in the last quarter. Finally, Intercontinental Wealth Advisors LLC purchased a new stake in Johnson & Johnson in the second quarter worth approximately $200,000. 65.89% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.